Visken (pindolol) / Novartis 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Visken (pindolol) / Novartis
2006-000523-34: Intensiv ikke-sympatikus aktiverende vasodilaterende behandling hos patienter med mikrovaskulær angina pectoris

Ongoing
4
115
Europe
Zanidip, Diovan, Doxazosin \"Stada\", Moxonidin \"Alpharma\", Visken, Sparkal, Selo-Zok, Myonil Retard, Isodur, Centyl med kaliumchlorid, Angicor, Zanidip, Diovan, Doxazosin \"Stada\", Moxonidin \"Alpharma\", Visken, Sparkal, Selo-Zok, Myonil Retard, Isodur, Centyl med kaliumchlorid, Angicor
Århus Sygehus
Patienter med hypertension og angina pectoris og ingen signifikante stenoser ved koronararteriografi (KAG).
 
 
NCT04767061: Impact of Beta-blockers on Physical Function in HFpEF

Completed
4
9
US
Beta blockers, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, nadolol, propranolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, sotalol, metoprolol succinate, metoprolol tartrate
Weill Medical College of Cornell University, The New York Community Trust
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
04/22
04/23
NCT04757584: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

Completed
4
9
US
Beta blockers, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, nadolol, propranolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, sotalol, metoprolol succinate, metoprolol tartrate
Weill Medical College of Cornell University, National Institute on Aging (NIA)
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
04/23
04/23
NCT01950520: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Completed
2
80
US
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qysmia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Volunteers
12/22
06/24
NCT06028321: Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)

Completed
1
51
Europe
Part 1 Group 1 Regime A (ACM-001.1), Part 1 Group 2 Regimen C (Pindolol), Part 2 Group D (Pindolol), Part 2 Group E (ACM-001.1), Part 2 Group F (ACM-001.1 ), Part 2 Group G (ACM-001.1), Part 1 Group 1 Regimen B (Pindolol), Part 1 Group 1 Regimen A (Placebo), Part 2 Group E (Placebo), Part 2 Group F (Placebo), Part 2 Group G ( Placebo)
Actimed Therapeutics Ltd, Quotient Sciences
Cachexia
06/22
06/22

Download Options